TScan Therapeutics, Inc. (TCRX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for hematologic and solid tumor malignancies. This report covers the quarterly period ended June 30, 2025. The Company is classified as an emerging growth company and a smaller reporting company. As of August 8, 2025, the Company had 52,471,405 shares of voting common stock and 4,276,588 shares of non-voting common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Revenue | $3,076 | $536 | $5,247 | $1,102 |
| Net Loss | $(36,952) | $(31,661) | $(71,079) | $(61,803) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.28) | $(0.55) | $(0.59) |
| Operating Expenses | $41,729 | $34,650 | $80,150 | $66,589 |
| Cash, Cash Equivalents & Marketable Securities | $218,045 | N/A | N/A | N/A |
| Long-Term Debt | $32,296 | N/A | N/A | N/A |
Note: Cash, cash equivalents, and marketable securities as of June 30, 2025, totaled $218.0 million (excluding $5.0 million restricted cash). The filing does not provide a specific Q2 2024 cash balance for direct comparison in the summary table, though the balance sheet shows $292.7 million in total current assets for Dec 31, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Collaboration and license revenue increased significantly to $3.1 million in Q2 2025 from $0.5 million in Q2 2024. This increase is attributed to the timing of research activities under the collaboration agreement with Amgen.
- Expense Increases: Total operating expenses rose by $7.1 million (20%) in Q2 2025 compared to Q2 2024.
- R&D Expenses: Increased by $5.8 million, driven primarily by a $3.8 million increase in laboratory supplies and studies (CDMO activities) and a $1.7 million increase in facility-related expenses due to the commencement of rent payments for expanded space in December 2024.
- G&A Expenses: Increased by $1.3 million, primarily due to additional headcount and stock-based compensation.
- Debt Refinancing: In December 2024, the Company terminated its K2 HealthVentures loan agreement and entered into a new $52.5 million term loan facility with Silicon Valley Bank (SVB), of which $32.5 million was funded. This resulted in a loss on extinguishment of the prior debt.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($218.0 million) are sufficient to fund operations into the first quarter of 2027.
- Development Pipeline: The Company is advancing TSC-101 for hematologic malignancies (AML, MDS, ALL) in the ALLOHA Phase 1 trial. For solid tumors, seven product candidates have advanced to Phase 1, and the FDA has cleared the IND for the multiplex T-Plex approach.
- Collaboration: The Amgen collaboration includes an upfront payment of $30 million (collected in 2023) and potential success-based milestones exceeding $500 million. Revenue is recognized over time based on research progress.
- Risks:
- Capital Needs: The Company expects to incur significant losses for the foreseeable future and will require substantial additional funding to complete development and commercialization.
- Regulatory & Clinical: Risks include failure of clinical trials, inability to obtain regulatory approval, and manufacturing complexities associated with cell therapies.
- Debt Covenants: The SVB loan agreement contains restrictive covenants limiting the Company's ability to incur additional debt, pay dividends, or make certain investments.
- Tax Legislation: The "One Big Beautiful Bill Act" enacted in July 2025 includes changes to R&D capitalization rules; the impact is currently being analyzed.
Investor Verification Checklist
- Cash Runway: Verify the $218 million cash position and the specific assumptions used to project funding sufficiency into Q1 2027.
- Amgen Revenue Recognition: Review the input method used to recognize revenue from the Amgen collaboration and the estimated total costs to complete the performance obligation.
- Debt Terms: Examine the specific financial and clinical milestones in the SVB loan agreement that could trigger acceleration or changes in the amortization schedule.
- R&D Spend Efficiency: Assess the $3.8 million increase in CDMO-related laboratory supplies against clinical trial enrollment progress and manufacturing yield rates.
- Tax Impact: Monitor updates regarding the impact of the July 2025 tax legislation on the Company's R&D capitalization and net operating loss carryforwards.